Variation of cost among anti-malarial drugs available in Indian market
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20194775Keywords:
Antimalarial drugs, Cost ratio, Percent cost variation, Indian marketAbstract
Background: There are numerous brands of antimalarial existent in the market. Expensive drugs could result in financial drain that causes reduced compliance or even non-compliance. Non-adherence to therapy could consequently cause partial treatment that leads to higher morbidity and in certain cases mortality too. Thus this evaluation was conducted to measure the cost disparity of malaria therapy.
Methods: The maximum and minimum price of each brand of the drug in Indian rupee rate was noted by using the latest edition of current index of medical specialities. The cost ratio and the percentage cost variation for individual drug brands were calculated.
Results: The analysis of data reflected a considerable cost variation among antimalarial drugs. Chloroquine DS 500 mg showed the highest cost ratio and cost variation (cost ratio=15.3 and % cost variation=1434). Overall injectable antimalarials showed considerable cost variation as compared to oral antimalarial agents.
Conclusions: The maximum variation shown by oral antimalarial was found to be for chloroquine DS 500 tablet. But there was significant price variation among injectable antimalarial. Injectable antimalarials are often the choice of drug when dealing with critically ill malaria patients specially when suffering from complicated malaria. So, such significant price variation creates burden on poor patients economically which leads to non-compliance and hence increased morbidity and mortality due to incomplete treatment.
References
Kumar L, Dinkar JK, Mohan L, Dikshit H. Cost variation analysis of antimalarial drugs available in India. Int J Res Med Sci. 2017;5(9):4051-4.
Tren R. Malaria and Climate Change. Working Papers Series: Julian Simon Centre for Policy Research. October 2002. Available at: http://www .libertyindia.org/pdfs/malaria_climatechange2002.pdf. Accessed on 1 September 2019.
PB Health. National Vector Borne Disease Control Programme. Available at: http://pbhealth.gov.in/pdf/ malaria.pdf. Accessed on 1 September 2019.
Dash AP, Valecha N, Anvikar AR, Umar A. Malaria in India: challenges and opportunities. J Biosci. 2008;33:583-92.
Sharma VP. Re-emergence of malaria in India. Indian J Med Res. 1996;103:26-45.
WHO. World Malaria Report 2014. WHO, Geneva. 2014. Available at: http://apps.who.int/iris/bitstream/ 10665/144852/2/9 789241564830_eng.pdf. Accessed on 1 September 2019.
Kumar A, Valecha N, Jain T, Dash AP. Burden of malaria in India: retrospective and prospective view. Am J Trop Med Hyg. 2007;77(6):69-78.
Malaria situation. National Vector Borne Disease control Programme. Available at http://nvbdcp.Gov .in/Doc/mal_situation_Jan2015.pdf. Accessed on 1 September 2019.
Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect. P. T. 2012;37:45-55.
Ahuja J, Gupta M, Gupta AK, Kohli K. Pharmacoeconomics. Natl Med J India. 2004;17:80-3.
Sanchez LS. Pharmacoeconomics: Principles, methods and applications. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey ML, eds. Pharmacotherapy: A pathophysiological approach. 7th ed. New York: McGraw Hill; 2008: 1-2.
Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160-3.
Chawan VS, Gawand KV, Badwane SV. Cost analysis of oral hypolipidemic agents available in India. Int J Basic Pharmacol. 2014:3:954-7.
Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort Hasen K, eds. A Textbook of Clinical Pharmacy Practice. 1st ed. Himayatnagar, Hyderabad: Orient Longman; 2004: 72.
Creese A, Kotwani A, Kutzin J, Pillay A. Evauating pharmaceuticals for health policy in low and middle-income country settings. In: Freemantle N, Hill S, eds. Evaluating pharmaceuticals for health policy and reimbursement. Massachusetts, USA: Blackwell Publication; 2004: 227-243.
Mahal A, Karan A, Engelgau M. The Economic Implications of Non-Communicable Disease for India. Washington, DC: World Bank; 2010.
Rataboli PV, Garg A. Confusing brand names: nightmare of medical profession. J Postgrad Med. 2005;51:13-6.
Drug Cost Control Order, 2013, Government of India. Available at: http://www.nppaindia.nic.in /DPCO2013. pdf. Accessed on 1 September 2019.
